肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Janssen收购BeneVir Biopharm以推进免疫治疗方案

2018-05-03 MedSci MedSci原创

JanssenBeneVirBiopharm免疫治疗
关注

Janssen签署了一份最终协议，收购一家私人控股的生物制药公司BeneVir Biopharm，该公司专注于开发溶瘤性免疫疗法。BeneVir利用专有的T-Stealth溶瘤病毒平台来设计能够感染和破坏癌细胞的溶瘤病毒。"溶瘤病毒免疫治疗通过激发和增强抗肿瘤免疫应答在治疗实体瘤方面具有令人兴奋的潜力，" Janssen研发部全球肿瘤治疗领域负责人Peter Lebowitz说。"BeneVir独


Janssen签署了一份最终协议，收购一家私人控股的生物制药公司BeneVir Biopharm，该公司专注于开发溶瘤性免疫疗法。

BeneVir利用专有的T-Stealth溶瘤病毒平台来设计能够感染和破坏癌细胞的溶瘤病毒。

"溶瘤病毒免疫治疗通过激发和增强抗肿瘤免疫应答在治疗实体瘤方面具有令人兴奋的潜力，" Janssen研发部全球肿瘤治疗领域负责人Peter Lebowitz说。"BeneVir独特的技术平台补充了我们的免疫肿瘤学研究，该研究致力于提出一系列新的免疫疗法和组合，以改善患者的治疗效果。"

Janssen表示，它打算推动临床前候选药物作为独立疗法，并与其他免疫疗法结合用于治疗实体肿瘤癌症（例如肺癌，前列腺癌，结肠直肠癌等）。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787467, encodeId=83261e8746765, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 14 22:37:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905053, encodeId=ebf5190505338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 17 05:37:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943688, encodeId=a141194368854, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Feb 12 16:37:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918061, encodeId=74c919180617e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 08:37:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707543, encodeId=dcae1e0754360, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Mon Jul 09 15:37:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Sat May 05 12:37:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311702, encodeId=5659311e020e, content=很好的消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/03/35bf7ee2cec5bfa8d6803a91d9565eaf.jpg, createdBy=15de2130189, createdName=1591fc9003m, createdTime=Thu May 03 21:48:50 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-08-14 jj000001

    #Pharm#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1787467, encodeId=83261e8746765, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 14 22:37:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905053, encodeId=ebf5190505338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 17 05:37:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943688, encodeId=a141194368854, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Feb 12 16:37:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918061, encodeId=74c919180617e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 08:37:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707543, encodeId=dcae1e0754360, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Mon Jul 09 15:37:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Sat May 05 12:37:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311702, encodeId=5659311e020e, content=很好的消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/03/35bf7ee2cec5bfa8d6803a91d9565eaf.jpg, createdBy=15de2130189, createdName=1591fc9003m, createdTime=Thu May 03 21:48:50 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2019-02-17 zhangjiqing

    #治疗方案#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1787467, encodeId=83261e8746765, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 14 22:37:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905053, encodeId=ebf5190505338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 17 05:37:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943688, encodeId=a141194368854, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Feb 12 16:37:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918061, encodeId=74c919180617e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 08:37:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707543, encodeId=dcae1e0754360, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Mon Jul 09 15:37:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Sat May 05 12:37:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311702, encodeId=5659311e020e, content=很好的消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/03/35bf7ee2cec5bfa8d6803a91d9565eaf.jpg, createdBy=15de2130189, createdName=1591fc9003m, createdTime=Thu May 03 21:48:50 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2019-02-12 许安

    #BeneVir#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1787467, encodeId=83261e8746765, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 14 22:37:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905053, encodeId=ebf5190505338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 17 05:37:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943688, encodeId=a141194368854, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Feb 12 16:37:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918061, encodeId=74c919180617e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 08:37:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707543, encodeId=dcae1e0754360, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Mon Jul 09 15:37:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Sat May 05 12:37:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311702, encodeId=5659311e020e, content=很好的消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/03/35bf7ee2cec5bfa8d6803a91d9565eaf.jpg, createdBy=15de2130189, createdName=1591fc9003m, createdTime=Thu May 03 21:48:50 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-06-09 sunylz

    #Bio#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1787467, encodeId=83261e8746765, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 14 22:37:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905053, encodeId=ebf5190505338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 17 05:37:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943688, encodeId=a141194368854, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Feb 12 16:37:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918061, encodeId=74c919180617e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 08:37:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707543, encodeId=dcae1e0754360, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Mon Jul 09 15:37:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Sat May 05 12:37:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311702, encodeId=5659311e020e, content=很好的消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/03/35bf7ee2cec5bfa8d6803a91d9565eaf.jpg, createdBy=15de2130189, createdName=1591fc9003m, createdTime=Thu May 03 21:48:50 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-07-09 124987c6m46暂无昵称

    #IOP#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1787467, encodeId=83261e8746765, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 14 22:37:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905053, encodeId=ebf5190505338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 17 05:37:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943688, encodeId=a141194368854, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Feb 12 16:37:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918061, encodeId=74c919180617e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 08:37:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707543, encodeId=dcae1e0754360, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Mon Jul 09 15:37:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Sat May 05 12:37:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311702, encodeId=5659311e020e, content=很好的消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/03/35bf7ee2cec5bfa8d6803a91d9565eaf.jpg, createdBy=15de2130189, createdName=1591fc9003m, createdTime=Thu May 03 21:48:50 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-05-05 zhang92564

    #Janssen#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1787467, encodeId=83261e8746765, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 14 22:37:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905053, encodeId=ebf5190505338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Feb 17 05:37:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943688, encodeId=a141194368854, content=<a href='/topic/show?id=89713341a9' target=_blank style='color:#2F92EE;'>#BeneVir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3341, encryptionId=89713341a9, topicName=BeneVir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Feb 12 16:37:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918061, encodeId=74c919180617e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 09 08:37:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707543, encodeId=dcae1e0754360, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Mon Jul 09 15:37:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527086, encodeId=abb9152e08616, content=<a href='/topic/show?id=ad4410248b5' target=_blank style='color:#2F92EE;'>#Janssen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10248, encryptionId=ad4410248b5, topicName=Janssen)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ca11798386, createdName=zhang92564, createdTime=Sat May 05 12:37:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311702, encodeId=5659311e020e, content=很好的消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/03/35bf7ee2cec5bfa8d6803a91d9565eaf.jpg, createdBy=15de2130189, createdName=1591fc9003m, createdTime=Thu May 03 21:48:50 CST 2018, time=2018-05-03, status=1, ipAttribution=)]
    2018-05-03 1591fc9003m

    很好的消息!

    0

相关资讯

Janssen的Imbruvica最终被纳入NHS

Janssen的Imbruvica将被纳入NHS，用于某些患有套细胞淋巴瘤（MCL）患者的常规治疗，此前成本监管机构已经为该药发布了最后的绿灯。在最后的指导方针中，英国国家医疗服务体系批准Imbruvica（ibrutinib）用于治疗只有这一种选择的患者。该机构之前表示，它不能为整个MCL患者群推荐该药，因为它没有提供NHS的资金价值，但是在二级保健中，Imbruvica可以被认为处于"临终"阈

Janssen购买了Legend的CART疗法

Janssen已经与Legend Biotech USA和Legend Biotech Ireland签署了一项全球协作和许可协议，开发，制造和销售实验性CART细胞疗法LCAR-B38M。目前，中国的监管机构正在对LCAR-B38M进行研究，该研究专门针对B细胞成熟抗原（BCMA），这是一种在骨髓瘤细胞中高表达的蛋白质，在美国临床研究的计划阶段正在进行多发性骨髓瘤的研究。根据协议条款，作为3.5